CN115315427A - Hpk1抑制剂及其制备方法和用途 - Google Patents

Hpk1抑制剂及其制备方法和用途 Download PDF

Info

Publication number
CN115315427A
CN115315427A CN202180023281.0A CN202180023281A CN115315427A CN 115315427 A CN115315427 A CN 115315427A CN 202180023281 A CN202180023281 A CN 202180023281A CN 115315427 A CN115315427 A CN 115315427A
Authority
CN
China
Prior art keywords
alkyl
substituted
pharmaceutically acceptable
group
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN202180023281.0A
Other languages
English (en)
Other versions
CN115315427B (zh
Inventor
谢雨礼
樊后兴
钱立晖
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Wigen Biomedicine Technology Shanghai Co Ltd
Original Assignee
Wigen Biomedicine Technology Shanghai Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wigen Biomedicine Technology Shanghai Co Ltd filed Critical Wigen Biomedicine Technology Shanghai Co Ltd
Publication of CN115315427A publication Critical patent/CN115315427A/zh
Application granted granted Critical
Publication of CN115315427B publication Critical patent/CN115315427B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5383—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic System
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Abstract

本发明涉及一种通式(1)所示的化合物及其制备方法，及如通式(1)所示的化合物或其各异构体、各晶型、药学上可接受的盐、水合物或溶剂合物作为HPK1抑制剂的用途。本发明化合物可用于制备治疗或者预防由HPK1介导的相关疾病。

Description

PCT国内申请，说明书已公开。

Claims (14)

  1. PCT国内申请，权利要求书已公开。
CN202180023281.0A 2020-04-20 2021-04-19 Hpk1抑制剂及其制备方法和用途 Active CN115315427B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN202010313871 2020-04-20
CN2020103138714 2020-04-20
PCT/CN2021/088098 WO2021213317A1 (zh) 2020-04-20 2021-04-19 Hpk1抑制剂及其制备方法和用途

Publications (2)

Publication Number Publication Date
CN115315427A true CN115315427A (zh) 2022-11-08
CN115315427B CN115315427B (zh) 2024-03-29

Family

ID=78270743

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202180023281.0A Active CN115315427B (zh) 2020-04-20 2021-04-19 Hpk1抑制剂及其制备方法和用途

Country Status (3)

Country Link
US (1) US20230130909A1 (zh)
CN (1) CN115315427B (zh)
WO (1) WO2021213317A1 (zh)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3873608A1 (en) 2018-10-31 2021-09-08 Gilead Sciences, Inc. Substituted 6-azabenzimidazole compounds having hpk1 inhibitory activity
CA3117556A1 (en) 2018-10-31 2020-05-07 Gilead Sciences, Inc. Substituted 6-azabenzimidazole compounds as hpk1 inhibitors
TWI826690B (zh) 2019-05-23 2023-12-21 美商基利科學股份有限公司 經取代之烯吲哚酮化物及其用途
WO2023083282A1 (zh) * 2021-11-12 2023-05-19 微境生物医药科技(上海)有限公司 作为hpk1抑制剂的稠环化合物
WO2023083299A1 (zh) * 2021-11-12 2023-05-19 微境生物医药科技(上海)有限公司 作为hpk1抑制剂的稠环化合物
WO2023207894A1 (en) * 2022-04-24 2023-11-02 Beigene , Ltd. POLYMORPH FORMS OF A 5H-PYRROLO [2, 3-b] PYRAZINE DERIVATIVE, METHODS OF PREPARATION, AND USES THEREFORE
WO2024002378A1 (zh) * 2022-07-01 2024-01-04 上海轶诺药业有限公司 一类具有激酶抑制功能的化合物及其制备和应用

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016197987A1 (zh) * 2015-06-12 2016-12-15 杭州英创医药科技有限公司 作为Syk抑制剂和/或Syk-HDAC双重抑制剂的杂环化合物
WO2018108083A1 (zh) * 2016-12-12 2018-06-21 杭州英创医药科技有限公司 作为Syk抑制剂和/或Syk-HDAC双重抑制剂的杂环化合物
WO2019238067A1 (en) * 2018-06-13 2019-12-19 Beigene, Ltd. Pyrrolo [2, 3-b] pyridines or pyrrolo [2, 3-b] pyrazines as hpk1 inhibitor and the use thereof
WO2021013083A1 (en) * 2019-07-17 2021-01-28 Beigene, Ltd. Tricyclic compounds as hpk1 inhibitor and the use thereof
CN115279760A (zh) * 2020-03-03 2022-11-01 轶诺(浙江)药业有限公司 新型hpk1抑制剂及其制备方法和应用

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016197987A1 (zh) * 2015-06-12 2016-12-15 杭州英创医药科技有限公司 作为Syk抑制剂和/或Syk-HDAC双重抑制剂的杂环化合物
WO2018108083A1 (zh) * 2016-12-12 2018-06-21 杭州英创医药科技有限公司 作为Syk抑制剂和/或Syk-HDAC双重抑制剂的杂环化合物
WO2019238067A1 (en) * 2018-06-13 2019-12-19 Beigene, Ltd. Pyrrolo [2, 3-b] pyridines or pyrrolo [2, 3-b] pyrazines as hpk1 inhibitor and the use thereof
WO2021013083A1 (en) * 2019-07-17 2021-01-28 Beigene, Ltd. Tricyclic compounds as hpk1 inhibitor and the use thereof
CN115279760A (zh) * 2020-03-03 2022-11-01 轶诺(浙江)药业有限公司 新型hpk1抑制剂及其制备方法和应用

Also Published As

Publication number Publication date
US20230130909A1 (en) 2023-04-27
CN115315427B (zh) 2024-03-29
WO2021213317A1 (zh) 2021-10-28

Similar Documents

Publication Publication Date Title
CN115315427B (zh) Hpk1抑制剂及其制备方法和用途
CN115335379B (zh) 含螺环的喹唑啉化合物
CN113767103B (zh) 新型螺环类K-Ras G12C抑制剂
WO2023280280A1 (zh) 作为KRas G12D抑制剂的稠环化合物
CN116390728B (zh) 喹唑啉衍生物及其制备方法和用途
CN113330009A (zh) 氮杂环化合物、其制备方法及用途
WO2021254384A1 (zh) 新型吡啶并[2，3-d]嘧啶-7(8H)-酮衍生物
CN115785068A (zh) Kif18a抑制剂
WO2022174765A1 (zh) 作为Wee-1抑制剂的稠环化合物
WO2022171088A1 (zh) 吡唑并[3,4-d]嘧啶-3-酮衍生物
CN115772159A (zh) Kif18a抑制剂
EP4159731A1 (en) New pyrazine compound
CN113880804A (zh) 新型苯并咪唑化合物
WO2022228511A1 (zh) 作为Wee-1抑制剂的稠环化合物及其制备方法和用途
CN113943288A (zh) 5,6-二氢吡嗪并[2,3-c]异喹啉化合物
WO2022262857A1 (zh) 芳基氧膦类化合物
WO2023143344A1 (zh) 新型egfr抑制剂
WO2023083373A1 (zh) 作为Src抑制剂的化合物
WO2022171126A1 (zh) 作为Wee-1抑制剂的稠环化合物
WO2022228512A1 (zh) 作为Wee-1抑制剂的吡咯并嘧啶衍生物
WO2023045942A1 (zh) 作为Wee-1抑制剂的1,2-二氢-3H-吡唑[3,4-d]嘧啶-3-酮化合物
WO2023134608A1 (zh) 作为hpk1抑制剂的稠环化合物
WO2022237843A1 (zh) Axl抑制剂
WO2023083299A1 (zh) 作为hpk1抑制剂的稠环化合物
WO2022171128A1 (zh) 作为Wee-1抑制剂的吡唑并[3,4-d]嘧啶-3-酮衍生物

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant